PLT Health Solutions Expands ceratiq® Benefits to Sensitive Skin and Dermal Density
Event summary
- PLT Health Solutions announced new clinical research on ceratiq® Phytoceramides, expanding benefits to include sensitive skin and dermal density.
- Two randomized clinical studies demonstrated improvements in transepidermal water loss (TEWL), erythema, dermal density, skin hydration, firmness, and wrinkle appearance.
- ceratiq has been evaluated in seven human clinical studies involving hundreds of participants across multiple independent research sites.
- The clinically supported daily dose of ceratiq is 350 mg, available in oil and powder formats for dietary supplements, functional foods, and beauty-from-within products.
The big picture
PLT Health Solutions is strengthening its position in the beauty-from-within market with robust clinical evidence supporting ceratiq's expanded benefits. The company's focus on sensitive skin and dermal density aligns with growing consumer demand for science-backed, holistic skincare solutions. With seven clinical studies and hundreds of participants, ceratiq's research program is unmatched in the phytoceramide category, providing a competitive edge in product development and marketing.
What we're watching
- Market Differentiation
- How ceratiq's expanded benefits will position it against competitors in the oral phytoceramide category.
- Consumer Adoption
- The pace at which consumers and product developers will integrate ceratiq's new benefits into their routines and formulations.
- Regulatory Compliance
- Whether the clinical evidence will support regulatory approvals and marketing claims in key markets.